ESK-001 Dose Level 5 for Plaque Psoriasis

Phase-Based Progress Estimates

Effectiveness

Safety

Plaque PsoriasisESK-001 - Drug

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

18 - 75

All Sexes

What conditions do you have?

Select

Eligibility

18 - 75

All Sexes

What conditions do you have?

Select

Study Summary

This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.

Eligible Conditions

Plaque Psoriasis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

VTX958 Dose B

SGX302 (Ointment with 0.25 % Hypericin)

JNJ-77242113

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 12 weeks

12 weeks

Heart rate

Psoriasis

To compare the Psoriasis Area and Severity Index (PASI-75) between doses of ESK-001 and placebo

8 weeks

To characterize the pharmacokinetics (PK) of ESK-001 (Cmax)

To characterize the pharmacokinetics (PK) of ESK-001 (Ctrough)

Trial Safety

Safety Progress

2 of 3

This is further along than 68% of similar trials

Similar Trials

VTX958 Dose B

SGX302 (Ointment with 0.25 % Hypericin)

JNJ-77242113

Trial Design

6 Treatment Groups

ESK-001 Dose Level 5

1 of 6

ESK-001 Dose Level 1

1 of 6

ESK-001 Dose Level 4

1 of 6

ESK-001 Dose Level 2

1 of 6

ESK-001 Dose Level 3

1 of 6

Placebo

1 of 6

Experimental Treatment

Non-Treatment Group

210 Total Participants · 6 Treatment Groups

Primary Treatment: ESK-001 Dose Level 5 · Has Placebo Group · Phase 2

ESK-001 Dose Level 5

Drug